A citation-based method for searching scientific literature

Dinesh Khanna, Christopher P Denton, Angelika Jahreis, Jacob M van Laar, Tracy M Frech, Marina E Anderson, Murray Baron, Lorinda Chung, Gerhard Fierlbeck, Santhanam Lakshminarayanan, Yannick Allanore, Janet E Pope, Gabriela Riemekasten, Virginia Steen, Ulf Müller-Ladner, Robert Lafyatis, Giuseppina Stifano, Helen Spotswood, Haiyin Chen-Harris, Sebastian Dziadek, Alyssa Morimoto, Thierry Sornasse, Jeffrey Siegel, Daniel E Furst. Lancet 2016
Times Cited: 285







List of co-cited articles
1060 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
380
48

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Donald P Tashkin, Michael D Roth, Philip J Clements, Daniel E Furst, Dinesh Khanna, Eric C Kleerup, Jonathan Goldin, Edgar Arriola, Elizabeth R Volkmann, Suzanne Kafaja,[...]. Lancet Respir Med 2016
379
41

Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P Tashkin, Robert Elashoff, Philip J Clements, Jonathan Goldin, Michael D Roth, Daniel E Furst, Edgar Arriola, Richard Silver, Charlie Strange, Marcy Bolster,[...]. N Engl J Med 2006
913
37

Update of EULAR recommendations for the treatment of systemic sclerosis.
Otylia Kowal-Bielecka, Jaap Fransen, Jerome Avouac, Mike Becker, Agnieszka Kulak, Yannick Allanore, Oliver Distler, Philip Clements, Maurizio Cutolo, Laszlo Czirjak,[...]. Ann Rheum Dis 2017
367
32

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
Dinesh Khanna, Christopher P Denton, Celia J F Lin, Jacob M van Laar, Tracy M Frech, Marina E Anderson, Murray Baron, Lorinda Chung, Gerhard Fierlbeck, Santhanam Lakshminarayanan,[...]. Ann Rheum Dis 2018
125
30

Systemic sclerosis.
Christopher P Denton, Dinesh Khanna. Lancet 2017
563
28

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Dinesh Khanna, Carlo Albera, Aryeh Fischer, Nader Khalidi, Ganesh Raghu, Lorinda Chung, Dan Chen, Elena Schiopu, Margit Tagliaferri, James R Seibold,[...]. J Rheumatol 2016
124
28

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Dinesh Khanna, Celia J F Lin, Daniel E Furst, Jonathan Goldin, Grace Kim, Masataka Kuwana, Yannick Allanore, Marco Matucci-Cerinic, Oliver Distler, Yoshihito Shima,[...]. Lancet Respir Med 2020
65
43

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Rachel K Hoyles, Ross W Ellis, Jessica Wellsbury, Belinda Lees, Pauline Newlands, Nicole S L Goh, Christopher Roberts, Sujal Desai, Ariane L Herrick, Neil J McHugh,[...]. Arthritis Rheum 2006
409
26

Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
Geetabali Sircar, Rudra Prosad Goswami, Dipankar Sircar, Alakendu Ghosh, Parasar Ghosh. Rheumatology (Oxford) 2018
74
32

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
399
23

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
Keith M Sullivan, Ellen A Goldmuntz, Lynette Keyes-Elstein, Peter A McSweeney, Ashley Pinckney, Beverly Welch, Maureen D Mayes, Richard A Nash, Leslie J Crofford, Barry Eggleston,[...]. N Engl J Med 2018
196
21

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
Jacob M van Laar, Dominique Farge, Jacob K Sont, Kamran Naraghi, Zora Marjanovic, Jérôme Larghero, Annemie J Schuerwegh, Erik W A Marijt, Madelon C Vonk, Anton V Schattenberg,[...]. JAMA 2014
343
21

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
Muriel Elhai, Marouane Boubaya, Oliver Distler, Vanessa Smith, Marco Matucci-Cerinic, Juan José Alegre Sancho, Marie-Elise Truchetet, Yolanda Braun-Moscovici, Florenzo Iannone, Pavel I Novikov,[...]. Ann Rheum Dis 2019
67
29

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Dinesh Khanna, Cathie Spino, Sindhu Johnson, Lorinda Chung, Michael L Whitfield, Christopher P Denton, Veronica Berrocal, Jennifer Franks, Bhavan Mehta, Jerry Molitor,[...]. Arthritis Rheumatol 2020
68
29

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
Donald P Tashkin, Robert Elashoff, Philip J Clements, Michael D Roth, Daniel E Furst, Richard M Silver, Jonathan Goldin, Edgar Arriola, Charlie Strange, Marcy B Bolster,[...]. Am J Respir Crit Care Med 2007
264
19

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Suzana Jordan, Jörg H W Distler, Britta Maurer, Dörte Huscher, Jacob M van Laar, Yannick Allanore, Oliver Distler. Ann Rheum Dis 2015
218
18

Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
Richard K Burt, Sanjiv J Shah, Karin Dill, Thomas Grant, Mihai Gheorghiade, James Schroeder, Robert Craig, Ikuo Hirano, Karin Marshall, Eric Ruderman,[...]. Lancet 2011
276
17

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.
Frank van den Hoogen, Dinesh Khanna, Jaap Fransen, Sindhu R Johnson, Murray Baron, Alan Tyndall, Marco Matucci-Cerinic, Raymond P Naden, Thomas A Medsger, Patricia E Carreira,[...]. Arthritis Rheum 2013
16

Interstitial lung disease in systemic sclerosis: a simple staging system.
Nicole S L Goh, Sujal R Desai, Srihari Veeraraghavan, David M Hansell, Susan J Copley, Toby M Maher, Tamera J Corte, Clare R Sander, Jonathan Ratoff, Anand Devaraj,[...]. Am J Respir Crit Care Med 2008
575
15

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
15

Mapping and predicting mortality from systemic sclerosis.
Muriel Elhai, Christophe Meune, Marouane Boubaya, Jérôme Avouac, Eric Hachulla, Alexandra Balbir-Gurman, Gabriela Riemekasten, Paolo Airò, Beatriz Joven, Serena Vettori,[...]. Ann Rheum Dis 2017
182
14

Treatment Algorithms for Systemic Sclerosis According to Experts.
Andreu Fernández-Codina, Kyle M Walker, Janet E Pope. Arthritis Rheumatol 2018
76
18

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.
Anthony J Tyndall, Bettina Bannert, Madelon Vonk, Paolo Airò, Franco Cozzi, Patricia E Carreira, Dominique Farge Bancel, Yannick Allanore, Ulf Müller-Ladner, Oliver Distler,[...]. Ann Rheum Dis 2010
614
14

Changes in causes of death in systemic sclerosis, 1972-2002.
Virginia D Steen, Thomas A Medsger. Ann Rheum Dis 2007
921
13

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
Christopher P Denton, Voon H Ong, Shiwen Xu, Haiyin Chen-Harris, Zora Modrusan, Robert Lafyatis, Dinesh Khanna, Angelika Jahreis, Jeffrey Siegel, Thierry Sornasse. Ann Rheum Dis 2018
57
22

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
Dimitrios Daoussis, Stamatis-Nick C Liossis, Athanassios C Tsamandas, Christina Kalogeropoulou, Alexandra Kazantzi, Chaido Sirinian, Maria Karampetsou, Georgios Yiannopoulos, Andrew P Andonopoulos. Rheumatology (Oxford) 2010
243
13

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
Dinesh Khanna, Yannick Allanore, Christopher P Denton, Masataka Kuwana, Marco Matucci-Cerinic, Janet E Pope, Tatsuya Atsumi, Radim Bečvář, László Czirják, Eric Hachulla,[...]. Ann Rheum Dis 2020
21
61

A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Dimitrios Daoussis, Konstantinos Melissaropoulos, Georgios Sakellaropoulos, Ioannis Antonopoulos, Theodora E Markatseli, Theodora Simopoulou, Panagiotis Georgiou, Andrew P Andonopoulos, Alexandros A Drosos, Lazaros Sakkas,[...]. Semin Arthritis Rheum 2017
93
12

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.
Frank van den Hoogen, Dinesh Khanna, Jaap Fransen, Sindhu R Johnson, Murray Baron, Alan Tyndall, Marco Matucci-Cerinic, Raymond P Naden, Thomas A Medsger, Patricia E Carreira,[...]. Ann Rheum Dis 2013
887
12

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Kristin B Highland, Oliver Distler, Masataka Kuwana, Yannick Allanore, Shervin Assassi, Arata Azuma, Arnaud Bourdin, Christopher P Denton, Jörg H W Distler, Anna Maria Hoffmann-Vold,[...]. Lancet Respir Med 2021
21
57

Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.
Muriel Elhai, Marine Meunier, Marco Matucci-Cerinic, Britta Maurer, Gabriela Riemekasten, Tifenn Leturcq, Raffaele Pellerito, Carlos Alberto Von Mühlen, Alessandra Vacca, Paolo Airo,[...]. Ann Rheum Dis 2013
105
11

Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
Jessica K Gordon, Viktor Martyanov, Jennifer M Franks, Elana J Bernstein, Jackie Szymonifka, Cynthia Magro, Horatio F Wildman, Tammara A Wood, Michael L Whitfield, Robert F Spiera. Arthritis Rheumatol 2018
43
25

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
11

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
William D Travis, Ulrich Costabel, David M Hansell, Talmadge E King, David A Lynch, Andrew G Nicholson, Christopher J Ryerson, Jay H Ryu, Moisés Selman, Athol U Wells,[...]. Am J Respir Crit Care Med 2013
11

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
Dinesh Khanna, Veronica J Berrocal, Edward H Giannini, James R Seibold, Peter A Merkel, Maureen D Mayes, Murray Baron, Philip J Clements, Virginia Steen, Shervin Assassi,[...]. Arthritis Rheumatol 2016
59
16

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
Nicole S Goh, Rachel K Hoyles, Christopher P Denton, David M Hansell, Elisabetta A Renzoni, Toby M Maher, Andrew G Nicholson, Athol U Wells. Arthritis Rheumatol 2017
123
10

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
Elizabeth R Volkmann, Donald P Tashkin, Myung Sim, Ning Li, Ellen Goldmuntz, Lynette Keyes-Elstein, Ashley Pinckney, Daniel E Furst, Philip J Clements, Dinesh Khanna,[...]. Ann Rheum Dis 2019
65
15

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.
Demosthenes Bouros, Athol U Wells, Andrew G Nicholson, Thomas V Colby, Vlasis Polychronopoulos, Panos Pantelidis, Patricia L Haslam, Dimitris A Vassilakis, Carol M Black, Roland M du Bois. Am J Respir Crit Care Med 2002
465
10

Systemic sclerosis.
Yannick Allanore, Robert Simms, Oliver Distler, Maria Trojanowska, Janet Pope, Christopher P Denton, John Varga. Nat Rev Dis Primers 2015
281
10

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.
Lisa M Rice, Cristina M Padilla, Sarah R McLaughlin, Allison Mathes, Jessica Ziemek, Salma Goummih, Sashidhar Nakerakanti, Michael York, Giuseppina Farina, Michael L Whitfield,[...]. J Clin Invest 2015
177
10

Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.
Aryeh Fischer, Kevin K Brown, Roland M Du Bois, Stephen K Frankel, Gregory P Cosgrove, Evans R Fernandez-Perez, Tristan J Huie, Mahalakshmi Krishnamoorthy, Richard T Meehan, Amy L Olson,[...]. J Rheumatol 2013
184
10

Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
Elizabeth R Volkmann, Donald P Tashkin, Ning Li, Michael D Roth, Dinesh Khanna, Anna-Maria Hoffmann-Vold, Grace Kim, Jonathan Goldin, Philip J Clements, Daniel E Furst,[...]. Arthritis Rheumatol 2017
56
17

Prediction of pulmonary complications and long-term survival in systemic sclerosis.
Svetlana I Nihtyanova, Benjamin E Schreiber, Voon H Ong, Daniel Rosenberg, Pia Moinzadeh, J Gerrard Coghlan, Athol U Wells, Christopher P Denton. Arthritis Rheumatol 2014
198
10

Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.
Matthieu Ponsoye, Camelia Frantz, Nadira Ruzehaji, Carole Nicco, Muriel Elhai, Barbara Ruiz, Anne Cauvet, Sonia Pezet, Marie Laure Brandely, Frédéric Batteux,[...]. Ann Rheum Dis 2016
36
25

Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
Angelo De Lauretis, Piersante Sestini, Panagiotis Pantelidis, Rachel Hoyles, David M Hansell, Nicole S L Goh, Christopher J Zappala, Dina Visca, Toby M Maher, Christopher P Denton,[...]. J Rheumatol 2013
125
9

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.
Pierre-Antoine Juge, Joyce S Lee, Esther Ebstein, Hiroshi Furukawa, Evgenia Dobrinskikh, Steven Gazal, Caroline Kannengiesser, Sébastien Ottaviani, Shomi Oka, Shigeto Tohma,[...]. N Engl J Med 2018
133
9

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Toby M Maher, Tamera J Corte, Aryeh Fischer, Michael Kreuter, David J Lederer, Maria Molina-Molina, Judit Axmann, Klaus-Uwe Kirchgaessler, Katerina Samara, Frank Gilberg,[...]. Lancet Respir Med 2020
146
9

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Peter Saunders, Vicky Tsipouri, Gregory J Keir, Deborah Ashby, Marcus D Flather, Helen Parfrey, Daphne Babalis, Elisabetta A Renzoni, Christopher P Denton, Athol U Wells,[...]. Trials 2017
62
14

Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.
Veronika K Jaeger, Elina G Wirz, Yannick Allanore, Philipp Rossbach, Gabriela Riemekasten, Eric Hachulla, Oliver Distler, Paolo Airò, Patricia E Carreira, Alexandra Balbir Gurman,[...]. PLoS One 2016
79
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.